poisar

Stocks · News reference

Artiva Biotherapeutics Says It Is Initiating Phase 3 Trial Of AlloNK Plus Rituximab In About 150 Refractory RA Patients In H2 2026; Expects Updated Phase 2a Data From At Least 20 RA Patients In H2 2026

BenzingaBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading